Resources Top 5: Investors look to back a winning horse as Richardson Street Group gets De Grey band back together
Health Check: Biotechs canter into November, but the ‘favourites’ have lead in their saddlebags
How the cheapest ETF investment strategy is minting millionaires
ASX Quarterly Tech Wrap: Acquisitions, deals and capital raises
Lunch Wrap: Miners fall behind as RBA race enters the final straight
ASX October Winners: Modest gains for ASX as Mount Ridley soars 967pc
Up, Up, Down, Down: Gold hit a record but will we look back on October as lithium’s turning point?
Dr Boreham’s Crucible: Nova Eye’s US vision sharpens as profits come into view
Hiring a car in Japan? Here are eight things to know
ASX Quarterly Medtech Wrap: Strong growth, fresh capital and key milestones
Contributors
Our Resident Experts
Mining
Up, Up, Down, Down: Gold hit a record but will we look back on October as lithium’s turning point?
Resources Top 5: Investors rush to board the Mount Ridley gallium train
Big Tech’s nuclear pivot: How Amazon, Google and Meta are powering the AI revolution
Kristie Batten: Sky’s the limit for Tallebung in hot tin market
Gold Digger: Gold demand keeps hitting new records, says World Gold Council
Featured in Mining
Tech
The biometric edge: Can algorithms help you crack the three-hour marathon?
Air traffic bombarded by cyber criminals every day
Back Australia: We either innovate, or we will stagnate … it’s that simple
Amazon bets on nuclear to power AI future as Australia dithers
‘Just do it again’: Nike launches ‘anti-gravity’ shoe tech to reclaim market edge
Featured in Tech
Health & Biotech
Dr Boreham’s Crucible: Nova Eye’s US vision sharpens as profits come into view
ASX Quarterly Medtech Wrap: Strong growth, fresh capital and key milestones
Health Check: Despite selling life-saving tech, Uscom faces its honourable demise
Health Kick Podcast: Cynata Therapeutics entering into major stem cell clinical catalysts
Scott Power (actually Iain Wilkie): CSL’s fall haunts ASX healthcare, but Morgans sees opportunities
Featured in Health & Biotech
Experts
Reasons why inflation is high and an interest rate cut is off the table for the RBA
Stock Tips: Energy, property and F1-fuelled momentum drive this week’s picks
Criterion: In fostering truly sustainable investments, ELM waters the flowers and not the weeds
How to follow Rinehart’s lead and play the critical minerals boom
Clever or crazy? How to crack the airline status game with one flight
Is Jerome Powell’s likely rate cut pause a warning?
Back Australia: We either innovate, or we will stagnate … it’s that simple
